Shares of BioMarin Pharmaceutical have moved -2.4% today, and are now trading at a price of $52.01. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 1,630,131 compared to the stock's average volume of 2,689,974.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. Based in San Rafael, United States the company has 3,040 full time employees and a market cap of $9,991,866,368.
The company is now trading -41.22% away from its average analyst target price of $88.48 per share. The 25 analysts following the stock have set target prices ranging from $55.0 to $122.0, and on average give BioMarin Pharmaceutical a rating of buy.
Over the last 12 months BMRN shares have declined by -19.1%, which represents a difference of -32.8% when compared to the S&P 500. The stock's 52 week high is $73.51 per share and its 52 week low is $50.76. Based on BioMarin Pharmaceutical's average net margin growth of 58.7% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 2,853,915 | 426,859 | 15 | 114.29 |
| 2023 | 2,419,226 | 167,645 | 7 | 0.0 |
| 2022 | 2,096,039 | 141,561 | 7 | 333.33 |
| 2021 | 1,846,275 | -64,080 | -3 | -106.52 |
| 2020 | 1,860,455 | 854,029 | 46 | 4700.0 |
| 2019 | 1,704,048 | -23,848 | -1 |
